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Current anticoagulant therapies have several caveats in the clinical use. New oral antithrombin
(Dabigatran) provides comparable or superior thromboprophylaxis in multiple thromboembolic
disease indications compared to standard of care.
Aim of this work: To evaluate the role of a new oral antithrombin, in management of thrombo-
philia presented with multiple infarctions (cerebral infarction, myocardial infarction, pulmonary
embolism or infarction).
Patient and methods: This work was done on 100 patients with thrombophilia associated with
multiple infarctions (cerebral infarction, myocardial infarction, pulmonary embolism or infarction).
They were divided into 2 groups Group I: treated by LMW heparin. Group II: treated by
dabigatran. The following was done for all patients. Thorough history taking, complete physical
examination, investigations including CT, D Dimer, INR, APTT, Platelet count, Chest X ray
P/A and lateral view, CT chest and/or Brain, ECG, CKMB and troponin when needed.
Results: The percentage of Stroke/TIA, AF/MI, PE, mixed and peripheral thrombotic events
were 30, 24, 23, 26 and 6 patients respectively.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.Introduction
Thrombin is a key serine protease and is the main effector pro-
tease in the blood coagulation cascade, exhibiting both pro-
and anti-coagulant properties [1]. Thrombin (FIIa) is gener-
ated via proteolytic cleavage from inactive prothrombin (FII)
by factor Xa (FXa) in the prothrombinase complex, which
256 M. Abdelwahab et al.assembles when circulating coagulation factors come into
contact with tissue factor (TF) on exposed extravascular
tissues. Thrombin plays a central role in the initiation and
propagation of thrombotic disease by activating platelets,
catalyzing ﬁbrinogen conversion into ﬁbrin, and promoting
clot stabilization [2]. Thrombin activates upstream factors in
the cascade to amplify the coagulation response and enhance
thrombin generation. Its activity is inhibited via endogenous
circulating anticoagulants including antithrombin (AT),
heparin cofactor II (HCII), and binding to cofactor thrombo-
modulin (TM) to activate the anticoagulant protein C [1].
Thromboembolic disease is a major cause of mortality and
morbidity in the developed world and is caused by an excessive
stimulation of coagulation. Since thrombin is a key serine pro-
tease in the coagulation cascade, numerous efforts have been
made to develop safe and effective orally active direct throm-
bin inhibitors (DTIs). Current anticoagulant therapy includes
the use of indirect thrombin inhibitors (e.g., heparins, and
low-molecular-weight-heparins) and vitamin K antagonists
such as warfarin. However there are several caveats in the clin-
ical use of these agents including narrow therapeutic window,
parenteral delivery, and food- and drug–drug interactions.
Dabigatran is a synthetic, reversible DTI with high afﬁnity
and speciﬁcity for its target binding both free and clot-bound
thrombin, and offers a favorable pharmacokinetic proﬁle.
Large randomized clinical trials have demonstrated that dabig-
atran provides comparable or superior thromboprophylaxis in
multiple thromboembolic diseases compared to standard anti-
coagulant. Dabigatran is the ﬁrst in a class of new oral antico-
agulant agents from the class of the direct thrombin inhibitors
to be licensed worldwide to prevent strokes in those with non-
valvular atrial ﬁbrillation, and at least one additional risk fac-
tor for stroke (congestive heart failure with left ventricular
ejection fraction <40%, elder age, hypertension, diabetes,
and prior stroke or transient ischemic attack or systemic embo-
lism), and to prevent the formation of venous thromboembo-
lism in adults who have had an orthopedic surgery with total
hip or knee replacement [3,4]. Except for the initial base line
INR, Dabigatran does not require INR monitoring as it is
unreliable in patients on dabigatran. This can be done through
thrombin time (TT), activated partial thromboplastin time
(aPTT) and ecarin clotting time (ECT) being the most sensitive
parameter for anticoagulant activity. The thrombin time (TT)
assay is extremely sensitive for accurate quantitative measure-
ment of dabigatran activity [5]. If ECT or TT is not available,
the aPTT test provides an approximation of dabigatran’s anti-
coagulant activity, an aPTT of >80 s at trough was associated
with an increased risk of bleeding [6]. Dabigatran dosing is
adjusted for kidney function as it is contraindicated in patients
with severe renal impairment (creatinine clearance <30 ml/
min), to minimize the risk of bleeding. A dose reduction and
close clinical surveillance should be considered in patients with
moderate renal impairment (creatinine clearance 30–50 ml/
min), particularly in those at an increased risk of bleeding,
and patients older than 75 years [7]. Patients with active path-
ological bleeding or with a known serious hypersensitivity
reaction (e.g., anaphylactic shock or reaction) to dabigatran.
patients who have lesions or conditions at a signiﬁcant risk
of major bleeding such as current or recent gastrointestinal
ulceration, recent brain or spinal injury, recent brain, spinal
suspected esophageal varices, arteriovenous malformations,
vascular aneurysms or major intraspinal or intracerebralvascular abnormalities. It is contraindicated in severe hepatic
impairment or liver disease as it is expected to have any impact
on survival [8]. Dabigatran must not be used in patients taking
oral or parenteral antifungal infections, ketoconazole and itr-
aconazole, or the immunosuppressant medicines cyclosporine
and tacrolimus [8]. Administration of a P-gp inducer (such
as rifampicin, phenytoin or carbamazepine) is expected to
result in decreased dabigatran concentrations and should be
avoided, use of dabigatran is contraindicated with droneda-
rone, and with other anticoagulants, except when switching
treatment to or from dabigatran, or with the use of unfraction-
ated heparin for maintenance of venous or arterial catheter
patency. The use of dabigatran during pregnancy or lactation
is not recommended [4].
Aim of this work
To evaluate the role of new oral antithrombin, in management
of thrombophilia presented with multiple infarctions (cerebral
infarction, myocardial infarction, pulmonary embolism or
infarction).
Patient and methods
This work was done on 100 patients with thrombophilia asso-
ciated with multiple infarctions (cerebral infarction, myocar-
dial infarction, pulmonary embolism or infarction). It was
done in either the Chest or Neurology Department, Tanta
University Hospital, Egypt from January 2011 to may 2013.
The patients were divided into two groups, group I included
34 patients treated with LMW heparin and group II included
66 patients treated with dabigatran. All the patients started
marevan after 3 days of treatment and continued together with
LMW heparin or dabigatran for other 3 days, then marevan
was given alone, some cases needed additional anti-platelet
such as clopidogrel. The following was done for all patients:
Thorough history taking, complete physical examination, the
following investigations: Clotting time (CT), D Dimer, INR,
APTT, platelet count, plain X-ray Chest P/A and lateral view.
CT Chest and/or Brain when needed. ECG, CK MB and
troponin when needed. Exclusion criteria were patients with
severe heart-valve disorder, stroke within 14 days or severe
stroke within 6 months, recent or known bleeding disorders,
uncontrolled hypertension, severe renal dysfunction with
creatinine clearance <30 ml/min, recent gastrointestinal ulcer-
ation, Esophageal varices, active liver disease and pregnant
women.
Statistics
Statistical presentation and analysis of the present study were
conducted, using the mean, standard deviation and t test linear
Correlation Coefﬁcient [r] and the SPSS V.16 (Figs. 1 and 2
and Tables 1–6).
Discussion
Thrombophilia is liability of blood to clot due to genetic or
acquired causes and can be presented as CVA, MI, PE and
peripheral thrombosis either single or mixed. In the present
work the percentage of Stroke/TIA, AF/MI, PE, mixed and
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Figure 1 Showing percentage of risk factors of thrombophilia of
the studied patients.
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Figure 2 Showing percentage of Stroke/TIA, AF/MI, PE, mixed
and peripheral thrombotic events were 30, 24, 23, 26 and 6 patients
respectively.
Table 1 Some demographic data of the studied patients (Age,
Sex and Body Weight).
Parameters Range Mean ±SD
Age 29–82 57.6 14.61
Sex (M/F) 64/36
Body Weight 61–140 93.9 22.29
Table 2 Some hematological ﬁndings of the studied patients
(Platelet, RBCs and INR).
Parameters Range Mean ±SD
Platelets 140–223 183.8 22.72
RBC 4.1–5.6 4.99 0.42
INR 1.1–2.1 1.58 0.34
Table 3 Risk factors of thrombophilia of the studied patients
(DM, HTN, dyslipidemia, Cardiac, Stress).
+VE N %
DM 46 46
HTN 27 27
Dyslipidemia 57 57
Cardiac 29 29
Stress 24 24
Table 4 Percentage of Thrombotic events for the studied
patients.
Thrombotic events N %
PE 23 23
AF/MI 24 24
TIA/stroke 30 30
Peripheral 6 6
Mixed 26 26
Table 5 Percentage of anticoagulants and antiplateletes
(Dabigatran, LMWH, Coumarins and Clopidogrel).
+VE N %
Dabigatran 66 66
LMWH 34 34
Marevan 100 100
Clopidogrel 61 61
Table 6 Side Effects of different medications used in the
studied patients.
Dabigatran LMWH Marevan
Major Bleeding 0 2 GIT bleeding 0
Minor Bleeding 2 Epistaxis 3 SC Hematoma 3
Gastric upset 5 0 3
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respectively. This percentage of cases was explained by referral
of cases to both neurology and pulmonology department [9].
Garnock-Jones, 2011 reported that dabigatran has a fast
onset of action with peak plasma concentrations 2–3 h after
ingestion with a half-life of 12–14 h. It does not require routine
coagulation monitoring; it has no drug-food interactions, is
not metabolized by cytochrome P 450 enzymes, and does not
require dose adjustment for moderate liver disease [10].
Our study proved to be a safe convenient and effective anti-
coagulant activity in thrombophilia compared with other oral
as well as LMWH, this was in accordance to Dahl et al. 2012;
Eriksson et al. 2012 and Fuji et al., 2010 who studied in more
than 10,000 patients in four phase trials of deep venous throm-
bosis (DVT) and pulmonary embolism (PE) prophylaxis in
major orthopedic surgery using dabigatran demonstrated a
good overall safety proﬁle [11–13].
Contrary to our study Ginsberg et al., 2009 [14] compared
dabigatran etexilate at 150 and 220 mg once daily (OAD) with
enoxaparin 30 mg twice daily (BID), as prophylaxis of DVT or
thrombus dissemination after total knee replacement (TKR),
dabigatran was inferior due to a greater number of distal
thromboses. However Eriksson et al., 2007 [15] found equiva-
lence on comparing dabigatran to 40 mg of enoxaparin, for
both thrombosis prevention and bleeding in total hip replace-
ment (THR) and TKR.
Recently trials demonstrated its superiority in the preven-
tion of major VTE (Friedman et al., 2010; Eriksson et al.,
2011). In countries where dabigatran etexilate is approved
for VTE prophylaxis it is recommended at a dose of 220 or
150 mg OAD for patients with renal impairment or taking a
258 M. Abdelwahab et al.Pgp inhibitor [16]. In the treatment of VTE 150 mg BID dabig-
atran etexilate was compared to standard warfarin treatment
(Schulman et al., 2009). In the acute treatment setting, all
patients received heparin or LMWH for a mean of 9 days prior
to treatment with an oral anticoagulant. Dabigatran demon-
strated the same efﬁcacy in thrombosis prevention with signif-
icantly less minor bleeding and similar major bleeding. The
extension studies RE-MEDY study (Dabigatran vs. warfarin)
and RE-SONATE study (Dabigatran vs. placebo) showed a
similar efﬁcacy and improved bleeding proﬁle compared to
warfarin, and a 92% relative risk reduction of recurrent VTE
with elevated clinically relevant non-major bleeding but no sta-
tistical difference in major bleeding compared to placebo
(Schulman et al., 2011) [17–18]. In the RE-LY study, 18,113
patients with atrial ﬁbrillation (AF) and at least one risk factor
for stroke were randomized between warfarin, 110 or 150 mg
BID dabigatran etexilate (Connolly et al., 2009). The 150 mg
BID dose showed superior efﬁcacy in stroke prevention and
systemic embolism with similar major bleeding rate compared
to well controlled warfarin. The 110 mg BID dose had a signif-
icantly lower major bleeding rate and the same efﬁcacy as war-
farin. Both doses showed a signiﬁcant (up to 70%) reduction
of intracranial hemorrhage and a reduction in life-threatening
bleeding. There was a non-signiﬁcant 12% mortality beneﬁt
(p= 0.051) with the 150 mg BID dose (Connolly et al.,
2010) [19,20].
These results were consistent across all patient groups,
including those with a prior history of stroke or transient
ischemic attack (Diener et al., 2010), patients previously on
warfarin, or those new to oral anticoagulation (Ezekowitz
et al., 2010) [21,22].
For stroke prevention, the FDA recommends a lower
therapeutic dose (75 mg BID) in patients with severe renal
impairment [creatinine clearance 15–30 ml/min] and no use
in patients with creatinine clearance under 15 ml/min. In
Europe two doses (150, 110 mg BID) exist which enable
tailored dosing and are contraindicated in patients with a
creatinine clearance below 30 ml/min.
Conclusions
Dabigatran etexilate is an oral, reversible, direct thrombin
inhibitor that inhibits both clot-bound and circulating throm-
bin. After oral administration, dabigatran has a fast onset of
action, reaching peak plasma concentrations within 0.5–2 h,
thereby potentially negating the need for initial treatment with
a rapidly acting injectable anticoagulant. The presence of
dabigatran in the blood can be detected by a prolonged TT
or aPTT, but the anticoagulation response is sufﬁciently pre-
dictable that routine coagulation monitoring is not required.
Dabigatran has a low potential for food and drug interactions,
a half-life of 12–14 h in patients with normal renal function
that permits once- or twice-daily administration, and a fast
offset of action. About 80% of the drug is excreted unchanged
by the kidneys.
Dabigatran etexilate has demonstrated non-inferiority and
safety similar to once-daily enoxaparin for the prevention of
VTE in patients undergoing hip and knee arthroplasty. Given
its efﬁcacy, safety proﬁle, and attractive pharmacological char-
acteristics, it has been approved for this indication in >75
countries worldwide. Dabigatran has demonstrated noninferi-
ority to and improved safety compared with warfarin for thetreatment of VTE and noninferiority to warfarin at a lower
dosage and superiority at a higher dose for preventing stroke
and systemic embolism in patients with nonvalvular
AF.Thrombin time (TT), has been approved for the quantita-
tive determination of dabigatran plasma levels. For patients
taking dabigatran who bleed, there is no speciﬁc antidote. Dis-
continuation of the drug and supportive measures usually suf-
ﬁce because the anticoagulant effect of dabigatran is short-
lived. In emergencies, dabigatran can be dialyzed; failing that,
nonspeciﬁc hemostatic agents such as rFVIIa and prothrombin
complex concentrates can be considered. In case of overdose,
the efﬁcacy of early administration of activated charcoal and
charcoal ﬁltration is undergoing clinical evaluation.
Outstanding issues relating to the use of dabigatran etexi-
late include the lack of a test of anticoagulant activity, lack
of an antidote, limited evaluation in patients with severe renal
impairment, interaction with other drugs that are substrates of
the p-glycoprotein transporter, and unknown long-term safety.
The long-term safety of dabigatran etexilate is being evaluated
in ongoing studies.Conﬂict of interest
None declared.References
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